Oncoinvent ASA (CHIX:ONCINO) EBIT: kr-136.08 Mil (TTM As of Dec. 2025)


CHIX:ONCINO Oncoinvent ASA CHIX:ONCINO
36 GF Score
Price kr1,039.91
GF Value kr20,399.27
! 4 Warning Signs
View Full Analysis

What is Oncoinvent ASA EBIT?

Oncoinvent ASA CHIX:ONCINO 36 EBIT is kr-136.08 Mil as of Dec. 2025. GuruFocus rates CHIX:ONCINO with a GF Score™ of 36/100 and a GF Value™ of kr20,399.27. The stock has 4 warning signs investors should review.

Oncoinvent ASA's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was kr-84.68 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was kr-136.08 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Oncoinvent ASA's annualized ROC % for the quarter that ended in Dec. 2025 was -487.84%. Oncoinvent ASA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -2,071.18%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Oncoinvent ASA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -254.05%.

Oncoinvent ASA  (CHIX:ONCINo) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Oncoinvent ASA's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-169.35 * ( 1 - 0% )/( (15.041 + 54.388)/ 2 )
=-169.35/34.7145
=-487.84 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=86.753 - 5.795 - ( 65.917 - max(0, 19.749 - 86.679+65.917))
=15.041

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=204.958 - 21.218 - ( 173.458 - max(0, 57.959 - 187.311+173.458))
=54.388

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Oncoinvent ASA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-169.35/( ( (0.075 + max(0.697, 0)) + (15.581 + max(-46.3, 0)) )/ 2 )
=-169.35/( ( 0.772 + 15.581 )/ 2 )
=-169.35/8.1765
=-2,071.18 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.685 + 0 + 15.761) - (5.795 + 0 + 13.954)
=0.697

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.992 + 0 + 7.792) - (21.218 + 0 + 33.866)
=-46.3

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Oncoinvent ASA's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-136.08/53.565
=-254.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncoinvent ASA EBIT Related Terms

Oncoinvent ASA EBIT Historical Data

* Premium members only.

The historical data trend for Oncoinvent ASA's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncoinvent ASA EBIT Chart

Oncoinvent ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -309.31 -301.80 -189.82 -140.12 -155.05

Oncoinvent ASA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -74.76 -83.77 -57.33 -51.41 -84.68

CHIX:ONCINO vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Oncoinvent ASA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncoinvent ASA EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncoinvent ASA's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Oncoinvent ASA's EV-to-EBIT falls into.


CHIX:ONCINO
36GF Score
Oncoinvent ASA CHIX:ONCINO
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncoinvent ASA EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-136.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr-136.08 Mil mean?
Oncoinvent ASA (CHIX:ONCINO) has a EBIT of kr-136.08 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Oncoinvent ASA.
Is Oncoinvent ASA's EBIT too high?
Oncoinvent ASA's current EBIT is kr-136.08 Mil. Overall, Oncoinvent ASA has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's EBIT compare to VRTX and REGN?
Oncoinvent ASA's EBIT of kr-136.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Oncoinvent ASA. Oncoinvent ASA's current EBIT is kr-136.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Oncoinvent ASA (CHIX:ONCINO) has a current EBIT of kr-136.08 Mil. The stock's GF Value™ is kr20,399.27, compared to a current price of kr1,039.91 — trading 94.9% below its estimated fair value. The current EBIT is kr-136.08 Mil. Oncoinvent ASA's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Oncoinvent ASA (CHIX:ONCINO), the current EBIT is kr-136.08 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncoinvent ASA (CHIX:ONCINO) Overvalued in 2026?

Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued. The current stock price of kr1,039.91 is trading 94.9% below its estimated GF Value™ of kr20,399.27.

Key valuation signals for CHIX:ONCINO:

  • EBIT: kr-136.08 Mil
  • GF Value™: kr20,399.27 vs. price of kr1,039.91 (94.9% below fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the CHIX:ONCINO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncoinvent ASA Business Description

Address Gullhaugveien 7, Oslo, NOR, 0484
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
36GF Score

Get the complete analysis for CHIX:ONCINO

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1,039.91
Price
kr20,399.27
GF Value